Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) and Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Institutional & Insider Ownership
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 63.7% of Guardian Pharmacy Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Crinetics Pharmaceuticals and Guardian Pharmacy Services”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crinetics Pharmaceuticals | $1.04 million | 3,212.99 | -$298.41 million | ($4.11) | -8.63 |
| Guardian Pharmacy Services | $1.23 billion | 1.36 | -$87.29 million | ($1.52) | -17.34 |
Guardian Pharmacy Services has higher revenue and earnings than Crinetics Pharmaceuticals. Guardian Pharmacy Services is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Crinetics Pharmaceuticals and Guardian Pharmacy Services’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crinetics Pharmaceuticals | N/A | -32.28% | -29.45% |
| Guardian Pharmacy Services | -6.90% | -52.41% | -24.17% |
Analyst Recommendations
This is a breakdown of current recommendations for Crinetics Pharmaceuticals and Guardian Pharmacy Services, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crinetics Pharmaceuticals | 0 | 2 | 6 | 0 | 2.75 |
| Guardian Pharmacy Services | 0 | 0 | 3 | 0 | 3.00 |
Crinetics Pharmaceuticals presently has a consensus price target of $65.33, suggesting a potential upside of 84.14%. Guardian Pharmacy Services has a consensus price target of $25.67, suggesting a potential downside of 2.59%. Given Crinetics Pharmaceuticals’ higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Guardian Pharmacy Services.
Summary
Crinetics Pharmaceuticals beats Guardian Pharmacy Services on 7 of the 13 factors compared between the two stocks.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
